Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 2/20 | 0.59 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 3/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1603534 | 0.81 | SLC16A3 (0.59) | SLC16A3CNR1CNR2ACHEPDE5A | |
| SCHEMBL1603997 | 0.80 | SLC16A3 (0.70) | SLC16A3CNR1CNR2ACHEPDE5A | |
| SCHEMBL22849648 | 0.77 | SLC16A3 (0.75) | SLC16A3CNR1CNR2ACHEPDE5A | |
| Maleic Acid SCHEMBL22832570 | 0.77 | SLC16A3 (0.59) | SLC16A3CNR1CNR2ACHEPDE5A | |
| Fumaric Acid SCHEMBL1604097 | 0.77 | SLC16A3 (0.59) | SLC16A3CNR1CNR2ACHEPDE5A | |
| Maleic Acid SCHEMBL1604096 | 0.77 | SLC16A3 (0.59) | SLC16A3CNR1CNR2ACHEPDE5A | |
| SCHEMBL927377 | 0.75 | SLC16A3 (0.72) | SLC16A3CNR1CNR2ACHEPDE5A | |
| SCHEMBL29562615 | 0.75 | SLC16A3 (0.72) | SLC16A3CNR1CNR2ACHEPDE5A | |
| Bindarit SCHEMBL187885 | 0.74 | SLC16A3 (1.00) | SLC16A3CNR1CNR2ACHESCN8A | |
| Bindarit SCHEMBL29387325 | 0.74 | SLC16A3 (1.00) | SLC16A3CNR1CNR2ACHESCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025859-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | Translatum Medicus Inc. (CA) | 2024-01-25 | — | — | US | disclosed |
| US-11753382-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | Translatum Medicus Inc. (CA) | 2023-09-12 | — | — | US | disclosed |
| US-20190336482-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS INC (CA) | 2019-11-07 | — | — | US | disclosed |
| EP-2262778-B1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CXCR1 AND P40 | ACRAF (IT) | 2019-08-21 | — | — | EP | disclosed |
| US-20180221339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS, INC. (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9255073-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-02-09 | — | — | US | disclosed |
| US-20130267704-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2013-10-10 | — | — | US | disclosed |
| US-8461194-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A. C. R. A. F. S. P. A. (IT) | 2013-06-11 | — | — | US | disclosed |
| US-20110082141-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN.ANG.FRANC. A.C.R.A.F. S.p.A. (IT) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | UACA, PDE6C, EYA3 | SLC16A3 4100/4885CNR1 995/4885CNR2 607/4885 |
| US-20130267704-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | SLC16A3 2082/4885CNR1 66/4885CNR2 146/4885 |
| US-11753382-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | PCMT1, ICMT, FNTA | SLC16A3 466/4885CNR1 3751/4885CNR2 2883/4885 |
| US-20240025859-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | PCMT1, ICMT, FNTA | SLC16A3 466/4885CNR1 3751/4885CNR2 2883/4885 |
| US-20190336482-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | UACA, PDE6C, EYA3 | SLC16A3 4100/4885CNR1 995/4885CNR2 607/4885 |
| US-20110082141-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | SLC16A3 2082/4885CNR1 66/4885CNR2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.